Meta-analy

Meta-analysis suggests extended thromboprophylaxis reduces risk of thrombosis and all-cause mortality in post-discharge patients with COVID-19

In post-discharge patients with coronavirus disease 2019 (COVID-19) at high risk of thromboembolism, extended thromboprophylaxis, primarily prophylactic use of anticoagulants for < 35 days, can significantly reduce the risk of thrombosis and all-cause mortality without increasing the risk of major bleeding events, according to a meta-analysis published in Thrombosis Research.  “This study is the first, to the best of our knowledge, to provide a comprehensive investigation of the effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19 based on evidenc...

Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination

A 19-year-old Japanese man was hospitalized for cardiogenic shock 28 days after receiving a second d...

Blood Pressure Responses During Exercise: Physiological Correlates and Clinical Implications

BACKGROUND Abnormal blood pressure (BP) responses to exercise can predict adverse cardiovascular out...


Search:
Date
Filters:
Targeting
9:22

Targeting CV risk factors with GLP-1 RAs in people with obesity

Presenter: A. Michael Lincoff
Diabetology
EASD 2022
Once weekl
7:36

Once weekly insulin: The ONWARDS 2 study

Presenter: Tina Vilsbøll
Diabetology
EASD 2022
Is HFpEF h
20:42

Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Presenter: Silvio Inzucchi
Diabetology
EASD 2022
Semaglutid
10:59

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

Presenter: Timothy Garvey
Diabetology
EASD 2022
Semaglutid
7:29

Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg

Diabetology
EASD 2022
Primary re
5:15

Primary results of the phase 3 KEYNOTE-412 study

Presenter: Jean-Pascal Machiels
Oncology
ESMO 2022
Let’s talk
8:42

Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising

Presenter: Othmar Moser
Diabetology
EASD 2022
Treatment
8:60

Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma

Presenter: John Haanen
Oncology
ESMO 2022
Effect of
5:55

Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity

Presenter: Ambarish Pandey
Diabetology
EASD 2022
The IPSOS
6:13

The IPSOS trial

Presenter: Siow Ming Lee
Oncology
ESMO 2022
Choices in
10:06

Choices in asthma and COPD care: How to maximize outcomes for patients

Presenter: Charlotte Suppli Ulrik
Respiratory
ERS 2022
A fresh lo
11:34

A fresh look at pulmonary hypertension: practical takeaways for patient management

Presenter: John Gerard Coghlan
Cardiology
ESC 2022
Facing ant
11:52

Facing anticoagulation dilemmas in venous thromboembolism

Presenter: Ingrid Pabinger
Cardiology
ESC 2022
Influenza
5:14

Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial

Presenter: Remo H. M. Furtado
Cardiology
ESC 2022
The import
6:20

The importance of optimal RAASi therapy in heart failure

Presenter: Dan Atar
Cardiology
ESC 2022
Chronic co
8:45

Chronic coronary syndrome: re-thinking treatment management and outcome priorities

Presenter: Athanasios John Manolis
Cardiology
ESC 2022
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato
Oncology
Treatment
3:27

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Cardiology
Alcohol se
6:32

Alcohol septal ablation in hypertrophic cardiomyopathy: past and future

Presenter: Hubert Seggewiss
Cardiology
The use of
3:35

The use of SGLT2 inhibitors in the prevention and treatment of heart failure

Presenter: Petar M. Seferovic
Cardiology
Direct myo
5:15

Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era?

Presenter: Iacopo Olivotto
Cardiology
Diagnostic
10:55

Diagnostic delay in pulmonary arterial hypertension

Presenter: Barbro Kjellström and Bodil Ivarsson
Clinical I
6:21

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Babak Dehestani
Internal Medicine
Associatio
20:17

Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events

Presenter: Michael Camilleri
Internal Medicine
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology